Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

U.S. Regulators Approve Subcutaneous Version of Takeda’s Velcade

By Pharmaceutical Processing | January 24, 2012

Takeda on Monday announced that the FDA approved a label update for Velcade (bortezomib) to include subcutaneous administration of the drug in all approved indications. “Subcutaneous Velcade is yet another advance in the management of patients with multiple myeloma (MM) or relapsed mantle cell lymphoma,” commented Karen Ferrante, Chief Medical Officer of Takeda subsidiary Millennium.

The approval was based on results from a late-stage trial that randomised 222 bortezomib-naïve patients with relapsed MM to receive Velcade either subcutanously or intravenously. The trial met its primary objective of demonstrating that single agent subcutaneous Velcade retained at least 60 percent of the overall response rate (ORR) after 4 cycles relative to single agent intravenous use of the drug. Takeda noted that the overall safety profile was similar between the two arms, but 38 percent of patients given subcutaneous Velcade experienced periperhal neuropathy compared to 53 percent of patients in the intravenous arm.

Under the terms of a co-development agreement, Millennium is responsible for commercialisation of Velcade in the U.S., while Johnson & Johnson’s Jannssen Pharmaceutical unit is responsible for commercialisation in Europe and the rest of the world, except in Japan where the drug is co-promoted with Takeda.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE